Long noncoding RNAs in prostate cancer: Overview and clinical implications

Asian Journal of Andrology

Volumn 18, Issue 4, 2016, Pages 568-574

  Malik, Bhavna ^a   Feng, Felix ^b,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

biomarker; long noncoding RNAs (lncRNAs); prostate cancer

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BRCA2 PROTEIN; C TERMINAL BINDING PROTEIN 1 ANTISENSE; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; LONG UNTRANSLATED RNA; METASTASIS ASSOCIATED LUNG ADENOCARCINOMA TRANSCRIPT 1; MICRORNA; MYC PROTEIN; NKX3 1 PROTEIN; PCGEM1 PROTEIN; PRNCR1 PROTEIN; PROTEIN; PRUNE2 PROTEIN; RNA POLYMERASE II; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR E2F1; TUMOR MARKER; UNCLASSIFIED DRUG;

BIOCHEMICAL RECURRENCE; CANCER PROGNOSIS; CANCER RECURRENCE; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CELL VIABILITY; CHROMATIN ASSEMBLY AND DISASSEMBLY; COLONY FORMATION; DIGITAL RECTAL EXAMINATION; DNA DAMAGE; ENHANCER REGION; GENE ACTIVATION; GENE EXPRESSION; HISTONE METHYLATION; HOMOLOGOUS RECOMBINATION; HUMAN; IN SITU HYBRIDIZATION; NONHUMAN; NUCLEOSOME; OPEN READING FRAME; PHENOTYPE; PROGNOSIS; PROMOTER REGION; PROSTATE CANCER; PROSTATE VOLUME; PROSTATECTOMY; REVIEW; RNA INTERFERENCE; RNA PROCESSING; RNA SPLICING; UPREGULATION; URINALYSIS; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; MALE; PATHOLOGY; PROSTATE TUMOR; TUMOR RECURRENCE;

BIOMARKERS, TUMOR; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; RNA, LONG NONCODING;

EID: 84977646199     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.4103/1008-682X.177123     Document Type: Review

References (80)

1. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, et al. The genomic complexity of primary human prostate cancer. Nature 2011; 470: 214-20
2. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487: 239-43
3. Phin S, Moore MW, Cotter PD. Genomic rearrangements of PTEN in prostate cancer. Front Oncol 2013; 3: 240
4. Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013; 31: 1748-57
5. Ecke TH, Schlechte HH, Schiemenz K, Sachs MD, Lenk SV, et al. TP53 gene mutations in prostate cancer progression. Anticancer Res 2010; 30: 1579-86
6. Sharma A, Yeow WS, Ertel A, Coleman I, Clegg N, et al. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest 2010; 120: 4478-92
7. Gasi Tandefelt D, Boormans J, Hermans K, Trapman J. ETS fusion genes in prostate cancer. Endocr Relat Cancer 2014; 21: R143-52
8. Friedlander TW, Roy R, Tomlins SA, Ngo VT, Kobayashi Y, et al. Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Res 2012; 72: 616-25
9. Consortium EP. An integrated encyclopedia of DNA elements in the human genome. Nature 2012; 489: 57-74
10. Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer 2011; 10: 38
11. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011; 12: 861-74
12. Gibb EA, Vucic EA, Enfield KS, Stewart GL, Lonergan KM, et al. Human cancer long non-coding RNA transcriptomes. PLoS One 2011; 6: e25915
13. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell 2009; 136: 629-41
14. Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, et al. The landscape of long noncoding RNAs in the human transcriptome. Nat Genet 2015; 47: 199-208
15. Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol 2011; 29: 742-9
16. Guttman M, Amit I, Garber M, French C, Lin MF, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 2009; 458: 223-7
17. Cabili MN, Trapnell C, Goff L, Koziol M, Tazon-Vega B, et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev 2011; 25: 1915-27
18. Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res 2012; 22: 1775-89
19. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010; 464: 1071-6
20. Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell 2010; 39: 925-38
21. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, et al. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 2010; 465: 1033-8
22. Wang D, Garcia-Bassets I, Benner C, Li W, Su X, et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 2011; 474: 390-4
23. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 2007; 129: 1311-23
24. Zhao J, Sun BK, Erwin JA, Song JJ, Lee JT. Polycomb proteins targeted by a short repeat RNA to the mouse X chromosome. Science 2008; 322: 750-6
25. Prensner JR, Zhao S, Erho N, Schipper M, Iyer MK, et al. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. Lancet Oncol 2014; 15: 1469-80
26. Bartolomei MS, Zemel S, Tilghman SM. Parental imprinting of the mouse H19 gene. Nature 1991; 351: 153-5
27. Brown CJ, Ballabio A, Rupert JL, Lafreniere RG, Grompe M, et al. A gene from the region of the human X inactivation centre is expressed exclusively from the inactive X chromosome. Nature 1991; 349: 38-44
28. Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, et al. The transcriptional landscape of the mammalian genome. Science 2005; 309: 1559-63
29. Cheng J, Kapranov P, Drenkow J, Dike S, Brubaker S, et al. Transcriptional maps of 10 human chromosomes at 5-nucleotide resolution. Science 2005; 308: 1149-54
30. Guttman M, Garber M, Levin JZ, Donaghey J, Robinson J, et al. Ab initio reconstruction of cell type-specific transcriptomes in mouse reveals the conserved multi-exonic structure of lincRNAs. Nat Biotechnol 2010; 28: 503-10
31. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 2010; 28: 511-5
32. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59: 5975-9
33. Ferreira LB, Palumbo A, de Mello KD, Sternberg C, Caetano MS, et al. PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling. BMC Cancer 2012; 12: 507
34. Salameh A, Lee AK, Cardo-Vila M, Nunes DN, Efstathiou E, et al. PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. Proc Natl Acad Sci U S A 2015; 112: 8403-8
35. Prensner JR, Iyer MK, Sahu A, Asangani IA, Cao Q, et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet 2013; 45: 1392-8
36. Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, et al. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res 2014; 74: 1651-60
37. Prensner JR, Chen W, Han S, Iyer MK, Cao Q, et al. The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc. Neoplasia 2014; 16: 900-8
38. Roberts CW, Orkin SH. The SWI/SNF complex-Chromatin and cancer. Nat Rev Cancer 2004; 4: 133-42
39. Bottcher R, Hoogland AM, Dits N, Verhoef EI, Kweldam C, et al. Novel long non-coding RNAs are specific diagnostic and prognostic markers for prostate cancer. Oncotarget 2015; 6: 4036-50
40. Mehra R, Shi Y, Udager AM, Prensner JR, Sahu A, et al. A novel RNA in situ hybridization assay for the long noncoding RNA SChLAP1 predicts poor clinical outcome after radical prostatectomy in clinically localized prostate cancer. Neoplasia 2014; 16: 1121-7
41. Srikantan V, Zou Z, Petrovics G, Xu L, Augustus M, et al. PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. Proc Natl Acad Sci U S A 2000; 97: 12216-21
42. Yang L, Lin C, Jin C, Yang JC, Tanasa B, et al. lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature 2013; 500: 598-602
43. Petrovics G, Zhang W, Makarem M, Street JP, Connelly R, et al. Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene 2004; 23: 605-11
44. Chung S, Nakagawa H, Uemura M, Piao L, Ashikawa K, et al. Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility. Cancer Sci 2011; 102: 245-52
45. Prensner JR, Sahu A, Iyer MK, Malik R, Chandler B, et al. The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. Oncotarget 2014; 5: 1434-8
46. Parolia A, Crea F, Xue H, Wang Y, Mo F, et al. The long non-coding RNA PCGEM1 is regulated by androgen receptor activity in vivo. Mol Cancer 2015; 14: 46
47. Hung CL, Wang LY, Yu YL, Chen HW, Srivastava S, et al. A long noncoding RNA connects c-Myc to tumor metabolism. Proc Natl Acad Sci U S A 2014; 111: 18697-702
48. Cui Z, Ren S, Lu J, Wang F, Xu W, et al. The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor. Urol Oncol 2013; 31: 1117-23
49. Takayama K, Horie-Inoue K, Katayama S, Suzuki T, Tsutsumi S, et al. Androgen-responsive long noncoding RNA CTBP1-AS promotes prostate cancer. EMBO J 2013; 32: 1665-80
50. Malik R, Patel L, Prensner JR, Shi Y, Iyer MK, et al. The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer. Mol Cancer Res 2014; 12: 1081-7
51. Sakurai K, Reon BJ, Anaya J, Dutta A. The lncRNA DRAIC/PCAT29 locus constitutes a tumor-suppressive nexus. Mol Cancer Res 2015; 13: 828-38
52. Chakravarty D, Sboner A, Nair SS, Giannopoulou E, Li R, et al. The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nat Commun 2014; 5: 5383
53. Ylipaa A, Kivinummi K, Kohvakka A, Annala M, Latonen L, et al. Transcriptome sequencing reveals PCAT5 as a novel ERG-regulated long noncoding RNA in prostate cancer. Cancer Res 2015; 75: 4026-31
54. Wang L, Han S, Jin G, Zhou X, Li M, et al. Linc00963: a novel, long non-coding RNA involved in the transition of prostate cancer from androgen-dependence to androgen-independence. Int J Oncol 2014; 44: 2041-9
55. Pasmant E, Laurendeau I, Heron D, Vidaud M, Vidaud D, et al. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res 2007; 67: 3963-9
56. Tano K, Akimitsu N. Long non-coding RNAs in cancer progression. Front Genet 2012; 3: 219
57. El Messaoudi-Aubert S, Nicholls J, Maertens GN, Brookes S, Bernstein E, et al. Role for the MOV10 RNA helicase in polycomb-mediated repression of the INK4a tumor suppressor. Nat Struct Mol Biol 2010; 17: 862-8
58. Yu W, Gius D, Onyango P, Muldoon-Jacobs K, Karp J, et al. Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature 2008; 451: 202-6
59. Yap KL, Li S, Munoz-Cabello AM, Raguz S, Zeng L, et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell 2010; 38: 662-74
60. Wan G, Mathur R, Hu X, Liu Y, Zhang X, et al. Long non-coding RNA ANRIL (CDKN2B-AS) is induced by the ATM-E2F1 signaling pathway. Cell Signal 2013; 25: 1086-95
61. Wilusz JE, Freier SM, Spector DL. 3' end processing of a long nuclear-retained noncoding RNA yields a tRNA-like cytoplasmic RNA. Cell 2008; 135: 919-32
62. Bernard D, Prasanth KV, Tripathi V, Colasse S, Nakamura T, et al. A long nuclear-retained non-coding RNA regulates synaptogenesis by modulating gene expression. EMBO J 2010; 29: 3082-93
63. Hutchinson JN, Ensminger AW, Clemson CM, Lynch CR, Lawrence JB, et al. A screen for nuclear transcripts identifies two linked noncoding RNAs associated with SC35 splicing domains. BMC Genomics 2007; 8: 39
64. Ji P, Diederichs S, Wang W, Boing S, Metzger R, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 2003; 22: 8031-41
65. Ren S, Liu Y, Xu W, Sun Y, Lu J, et al. Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer. J Urol 2013; 190: 2278-87
66. Mourtada-Maarabouni M, Pickard MR, Hedge VL, Farzaneh F, Williams GT. GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene 2009; 28: 195-208
67. Zhou Y, Zhang X, Klibanski A. MEG3 noncoding RNA: a tumor suppressor. J Mol Endocrinol 2012; 48: R45-53
68. Zhou Y, Zhong Y, Wang Y, Zhang X, Batista DL, et al. Activation of p53 by MEG3 non-coding RNA. J Biol Chem 2007; 282: 24731-42
69. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006; 52: 1089-95
70. Deras IL, Aubin SM, Blase A, Day JR, Koo S, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008; 179: 1587-92
71. Chun FK, de la Taille A, van Poppel H, Marberger M, Stenzl A, et al. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol 2009; 56: 659-67
72. Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008; 54: 1081-8
73. Hessels D, Schalken JA. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol 2009; 6: 255-61
74. Luo Y, Gou X, Huang P, Mou C. The PCA3 test for guiding repeat biopsy of prostate cancer and its cut-off score: a systematic review and meta-analysis. Asian J Androl 2014; 16: 487-92
75. Wei JT, Feng Z, Partin AW, Brown E, Thompson I, et al. Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J Clin Oncol 2014; 32: 4066-72
76. Tosoian JJ, Ross AE, Sokoll LJ, Partin AW, Pavlovich CP. Urinary biomarkers for prostate cancer. Urol Clin North Am 2016; 43: 17-38
77. Mehra R, Udager AM, Ahearn TU, Cao X, Feng FY, et al. Overexpression of the long non-coding RNA SChLAP1 independently predicts lethal prostate cancer. Eur Urol 2015; S0302-2838(15)01211-7. [Doi: 10.1016/j.eururo.2015.12.003] [Epub ahead of print]
78. Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 2015; 373: 1697-708
79. McClorey G, Wood MJ. An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies. Curr Opin Pharmacol 2015; 24: 52-8
80. Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G. Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev 2015; 87: 108-19